NVO
NOVO (NVO) NORDISK's Cagrisema Beats Tirzepatide On Weight Loss In Trial
Phase 3 data show Novo's investigational CagriSema outperformed Eli Lilly's tirzepatide on weight loss in diabetes patients and beat placebo in obesity.
NVO
Market-moving news on Novo Nordisk (NYSE: NVO): filings, earnings, deals and other events, from REDFILED.
NVO
CHMP Backs EU Approval of NOVO NORDISK Haemophilia Drug Frehemgo
European regulators' advisory committee recommended marketing authorisation for denecimig, with first European launches planned for the fourth quarter of 2026.
NVO
NOVO NORDISK Semaglutide Trial in Children Aged 6 to 11 Hits Endpoint
In the STEP Young phase 3 trial, 40.4% of children treated with semaglutide were no longer classified as having obesity after 68 weeks, versus none on placebo.
NVO
NOVO NORDISK Completes Phase 3 Trial of CagriSema Against Tirzepatide
The Danish drugmaker's head-to-head Phase 3 study of CagriSema versus Eli Lilly's tirzepatide in type 2 diabetes is now listed as completed.